Novo Nordisk and AWS partner on AI drug discovery
Novo Nordisk said on Aug. 10, 2026, that it will partner with Amazon Web Services to speed up AI-driven drug discovery, a move that comes as its semaglutide business faces price pressure in the US.
Novo Nordisk announced on Aug. 10, 2026, that it has entered a strategic partnership with Amazon Web Services aimed at accelerating drug discovery through artificial intelligence [1]. The announcement appears in the company's official news archive as a press release dated that day, listed among dozens of other 2026 disclosures [1].
The source available for this story is limited to the headline and date of the release itself; it does not include the financial terms of the deal, the specific AI tools or cloud infrastructure involved, or which disease areas beyond drug discovery in general the partnership will target [1]. Those details are not yet known from the material provided.
The AWS announcement landed less than a week after Novo Nordisk reported second-quarter 2026 results. The company posted an adjusted operating profit of DKK 33,389 million for Q2 2026 and raised its full-year outlook, according to a separate company announcement dated Aug. 4, 2026 [1]. A companion release the same day confirmed the company raised its adjusted sales and adjusted operating profit outlook for 2026 [1]. The archive does not specify how much of that profit is tied to semaglutide products such as Ozempic, Wegovy, or Rybelsus, nor does it break out US sales trends separately [1].
The broader news feed also shows Novo Nordisk was active on multiple fronts around the same period. In September 2026, the company announced a corporate rebrand to "Novo" alongside an updated corporate culture [1], and it released Phase 3 STEP Young data showing that 40.4% of children living with obesity achieved a body mass index below the obesity threshold after treatment with semaglutide combined with lifestyle changes [1]. In July 2026, the company said it took action to stop what it called misleading national GLP-1 advertising campaigns by Eli Lilly [1]. None of these releases directly explain the AWS deal's scope or cost, and the archive listing does not connect the AI partnership to any specific pricing announcement for US patients [1].
Why it matters for patients
For people currently taking or considering semaglutide products, this announcement is about where Novo Nordisk is investing corporate resources, not about a change to current prescriptions, dosing, or price today. The source material does not show any immediate change to how Ozempic, Wegovy, or Rybelsus are priced, covered by insurance, or supplied in the US as a direct result of the AWS partnership [1].
The timing is notable because it comes alongside a raised financial outlook and rising profit figures for the same quarter [1], which suggests the company sees room to invest in long-term research infrastructure even as it manages business pressures. Whether AI-driven drug discovery translates into new treatments, different pricing strategies, or faster development of future GLP-1 medicines is not addressed in the available material and is not yet known.
What happens next
The press release entry itself provides no follow-up timeline for the AWS partnership [1]. Based on the archive, subsequent company news included the STEP Young Phase 3 data released Sept. 7, 2026, and the corporate rebrand to "Novo" announced Sept. 14, 2026 [1], though neither release directly references the AI collaboration. Further specifics on the AWS partnership's scope, cost, or effect on drug pricing were not found in the sources reviewed and remain unknown at this time.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.